Skip to main content

Dr. Bhatti is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bhatti's full profile

Already have an account?

  • Office

    99 North La Cienega Blvd
    Suite 200
    Beverly Hills, CA 90211
    Phone+1 310-657-9353
    Fax+1 310-657-9367

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 1996 - 1998
  • University of California (San Diego) Medical Center
    University of California (San Diego) Medical CenterResidency, Internal Medicine, 1994 - 1996
  • Stony Brook Medicine/University Hospital
    Stony Brook Medicine/University HospitalInternship, Internal Medicine, 1993 - 1994
  • UCLA School of Medicine
    UCLA School of MedicinePh.D, Immunology nd Microbiology, 1986 - 1992
  • UCLA School of Medicine
    UCLA School of MedicinePh.D., Microbiology and Immunology, 1986 - 1992
  • King Edward Medical University
    King Edward Medical UniversityClass of 1983

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1995 - 2025
  • National Board of Physicians and Surgeons Infectious Disease
  • National Board of Physicians and Surgeons Internal Medicine

Awards, Honors, & Recognition

  • Ph.D UCLA School of Medicine, 1993
  • Commendation for Dedicated Clinical Service to the County of Los Angeles 2006
  • Fellow American Association of University Women, 1990
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Turquoise-! Part 1b: Ombitasvir/Paritapavir/Ritonavir and Dasabuvir with Ribavarin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir  
    Wyles D., Saag M., Viani R.M., Lalezari J., Adeyemi O., Bhatti L., Khatri A., King J.R., Hu Y.B., Trinh R., Shulman N.S., and Ruane P, JID, 1/1/2017
  • Ombitasvir Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 - A Randomized Trial  
    Sulkowski M.S., Eron J.J., Wyles D., Trinh R., Lalezari J., Wang C., Slim J., Bhatti L., Gathe J., Ruane P.J., Elion R., Breedek F., Breenan R., Gary B., Khatri A., Gi..., JAMA, 1/1/2015
  • Once Daily Nevirapine XR: A Brief Overview of the Safety and Efficacy of a New Formulation  
    Bhatti, L, and J. Gladstein, Journal of the International Association of Physicians in Aids Care, 1/1/2012
  • Join now to see all

Abstracts/Posters

  • Pilot Study Evaluating the Safety and Efficacy of Dose Sparing Intradermal Administration of Influenza Vaccine in HIV-Positive Patients.
    Khanlou,H., S. Sanchez, M. Babaie, C. Chien, J.C. Ricaurte, T. Stein, L. Bhatti, P. Denouden, A. Voskanian and C. Farthing, CROI, 1/1/2006

Lectures

  • Efficacy and Safety of Switching from Boosted-protease Inhibitor Plus Emtricitabine/Tenofovir Disoproxil Fumarate Regimens to the Single-tablet Regimen of Darunavir/Co... 
    Paris, France - 1/23/2017
  • TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r+Dasabuvir+RBV for HCV/HIV Coinfection. 
    Boston, MA, 2016; Mendoza, Argentina, 2016 - 1/22/2016
  • Improvement in Liver Fibrosis, Necroinflammatory Scores and Liver Function Tests in Achieving SVR with DAA Treatment in HIV/HEP-C Co-infected Patients in a Ryan White ... 
    Moran, WY - 1/15/2016
  • Join now to see all

Committees

  • Advisory Committee Member, Aids Drug Assistance Program (ADAP) California

Professional Memberships

Other Languages

  • Urdu, Hindi, Punjabi